Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
US9717735B2 · kind B2 · utility
12Cited by
19References
60Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 17, 2015 |
| Grant date | Aug 1, 2017 |
| Priority date | — |
| Expiry date | Apr 17, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.